Engineers Gate Manager LP Purchases Shares of 18,051 Theravance Biopharma, Inc. (NASDAQ:TBPH)
Engineers Gate Manager LP purchased a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 18,051 shares of the biopharmaceutical company’s stock, valued at approximately $321,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. increased its stake in Theravance Biopharma by 3.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 323,578 shares of the biopharmaceutical company’s stock valued at $5,750,000 after purchasing an additional 10,014 shares in the last quarter. Laurion Capital Management LP increased its stake in Theravance Biopharma by 3,191.6% in the fourth quarter. Laurion Capital Management LP now owns 641,235 shares of the biopharmaceutical company’s stock valued at $11,395,000 after purchasing an additional 621,754 shares in the last quarter. Allstate Corp bought a new stake in Theravance Biopharma in the fourth quarter valued at $220,000. CWM Advisors LLC bought a new stake in Theravance Biopharma in the fourth quarter valued at $208,000. Finally, Penserra Capital Management LLC increased its stake in Theravance Biopharma by 170.3% in the fourth quarter. Penserra Capital Management LLC now owns 1,465 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 923 shares in the last quarter. 80.41% of the stock is owned by hedge funds and other institutional investors.
Theravance Biopharma stock opened at $21.55 on Thursday. Theravance Biopharma, Inc. has a fifty-two week low of $14.48 and a fifty-two week high of $31.35. The stock has a market cap of $1.41 billion, a PE ratio of -4.56 and a beta of 0.94. The firm’s 50-day simple moving average is $19.56 and its 200 day simple moving average is $18.36.
TBPH has been the subject of several recent research reports. SVB Leerink decreased their target price on shares of Theravance Biopharma from $41.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, April 1st. Morgan Stanley decreased their target price on shares of Theravance Biopharma from $31.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, March 8th. Finally, Zacks Investment Research downgraded shares of Theravance Biopharma from a “hold” rating to a “strong sell” rating and set a $15.00 target price for the company. in a research report on Monday, January 18th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Theravance Biopharma presently has a consensus rating of “Buy” and a consensus price target of $31.00.
In other Theravance Biopharma news, SVP Philip D. Worboys sold 8,829 shares of the business’s stock in a transaction dated Tuesday, March 9th. The shares were sold at an average price of $20.00, for a total value of $176,580.00. Following the transaction, the senior vice president now directly owns 343,679 shares in the company, valued at $6,873,580. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by insiders.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD).
Recommended Story: Can systematic risk be avoided?
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.